Exploratory dose-response study in endometriosis patients

• Research type

  Research Study

• Full title

  A randomised, placebo-controlled, double-blind, parallel-group, multicentre, exploratory dose-response study to assess the efficacy and safety of different oral doses of BAY 1128688 in women with symptomatic endometriosis over a 12-week treatment period

• IRAS ID

  223211

• Contact name

  Christian Becker

• Contact email

  christian.becker@obs-gyn.ox.ac.uk

• Sponsor organisation

  Bayer Healthcare AG

• Eudract number

  2017-000244-18

• Duration of Study in the UK

  1 years, 5 months, 5 days

• Research summary

  The purpose of the study is to test whether study drug BAY1128688 brings relief for pain to women with endometriosis and if so to get a first impression which dose(s) work best.

• REC name

  East Midlands - Leicester Central Research Ethics Committee

• REC reference

  17/EM/0339

• Date of REC Opinion

  25 Sep 2017

• REC opinion

  Further Information Favourable Opinion